Trexquant Investment LP Increases Stock Holdings in Aurinia Pharmaceuticals Inc $AUPH

Key Points

• Trexquant Investment LP increased its stake in Aurinia Pharmaceuticals by 58.5% during the first quarter, owning 700,638 shares valued at approximately $5.6 million.
• Aurinia Pharmaceuticals recently reported earnings of $0.16 per share, slightly below the expected $0.17, and indicated a revenue of $70.01 million for the quarter.
• Several analysts raised their price targets for Aurinia Pharmaceuticals, with Royal Bank Of Canada now setting a new target of $9.00 and HC Wainwright maintaining a buy rating with a target of $17.00.

Trexquant Investment LP grew its holdings in shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP by 58.5% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 700,638 shares of the biotechnology company's stock after purchasing an additional 258,620 shares during the quarter. Trexquant Investment LP owned approximately 0.51% of Aurinia Pharmaceuticals worth $5,633,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in AUPH. GF Fund Management CO. LTD. purchased a new stake in Aurinia Pharmaceuticals in the 4th quarter worth about $27,000. Tower Research Capital LLC TRC boosted its position in shares of Aurinia Pharmaceuticals by 368.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company's stock valued at $30,000 after acquiring an additional 2,635 shares during the last quarter. Vermillion & White Wealth Management Group LLC purchased a new position in shares of Aurinia Pharmaceuticals during the 4th quarter valued at about $31,000. GAMMA Investing LLC raised its holdings in shares of Aurinia Pharmaceuticals by 56.1% during the 1st quarter. GAMMA Investing LLC now owns 4,852 shares of the biotechnology company's stock valued at $39,000 after buying an additional 1,744 shares in the last quarter. Finally, USA Financial Formulas purchased a new position in shares of Aurinia Pharmaceuticals during the 1st quarter valued at about $50,000. Hedge funds and other institutional investors own 36.83% of the company's stock.

Aurinia Pharmaceuticals Stock Down 1.0%

AUPH stock traded down $0.13 during midday trading on Friday, hitting $12.40. The stock had a trading volume of 1,825,129 shares, compared to its average volume of 1,785,721. The firm has a market cap of $1.63 billion, a price-to-earnings ratio of 28.84 and a beta of 1.26. The business has a 50-day moving average of $10.28 and a two-hundred day moving average of $8.82. Aurinia Pharmaceuticals Inc has a 52-week low of $6.42 and a 52-week high of $12.82. The company has a debt-to-equity ratio of 0.18, a current ratio of 5.23 and a quick ratio of 4.63.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last released its earnings results on Thursday, July 31st. The biotechnology company reported $0.16 EPS for the quarter, missing the consensus estimate of $0.17 by ($0.01). Aurinia Pharmaceuticals had a return on equity of 20.06% and a net margin of 23.31%.The company had revenue of $70.01 million during the quarter, compared to the consensus estimate of $64.27 million. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that Aurinia Pharmaceuticals Inc will post 0.11 earnings per share for the current fiscal year.

Insider Activity at Aurinia Pharmaceuticals

In other Aurinia Pharmaceuticals news, Director Kevin Tang acquired 200,000 shares of the company's stock in a transaction that occurred on Tuesday, August 5th. The shares were bought at an average cost of $11.68 per share, with a total value of $2,336,000.00. Following the completion of the transaction, the director directly owned 11,329,500 shares of the company's stock, valued at approximately $132,328,560. This represents a 1.80% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders acquired 1,300,000 shares of company stock worth $13,590,000 over the last 90 days. Company insiders own 12.20% of the company's stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the company. HC Wainwright reaffirmed a "buy" rating and issued a $17.00 price target on shares of Aurinia Pharmaceuticals in a research note on Wednesday, July 30th. Royal Bank Of Canada boosted their target price on Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the company an "outperform" rating in a research note on Friday, August 1st. Three investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $12.00.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.